Leukemia Research
Volume 27, Issue 3 , Pages 259-266 , March 2003

N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL)

  • Stefan Faderl

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, P.O. Box 428, 1515 Holcombe Blvd., Houston, TX 77030, USA
    • ,
  • Reuben Lotan

      Affiliations

    • Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, P.O. Box 422, 1515 Holcombe Blvd., Houston, TX 77030, USA
    • ,
  • Hagop M. Kantarjian

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, P.O. Box 428, 1515 Holcombe Blvd., Houston, TX 77030, USA
    • ,
  • David Harris

      Affiliations

    • Department of Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, P.O. Box 422, 1515 Holcombe Blvd., Houston, TX 77030, USA
    • ,
  • Quin Van

      Affiliations

    • Department of Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, P.O. Box 422, 1515 Holcombe Blvd., Houston, TX 77030, USA
    • ,
  • Zeev Estrov

      Affiliations

    • Department of Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, P.O. Box 422, 1515 Holcombe Blvd., Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-713-794-1675; fax: +1-713-745-2374.

Received 26 December 2001 ,Accepted 6 June 2002.

References 

  1. Estey E. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 2000;14:476–479
  2. Kantarjian HM, O’Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al.  Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphoblastic leukemia. J. Clin. Oncol. 2000;18:547–561
  3. Greenberg ER, Sporn MB. Antioxidant vitamins, cancer, and cardiovascular disease. N. Engl. J. Med. 1996;334:1189–1190
  4. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al.  Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation. N. Engl. J. Med. 1999;341:1165–1173
  5. Lo Coco F, Nervi C, Avvisati G, Mandelli F. Acute promyelocytic leukemia: a curable disease. Leukemia. 1998;12:1866–1880
  6. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science. 1997;278:1073–1077
  7. Robertson KM, Penland SN, Padilla GM, Selvan RS, Kim CS, Fine RL, et al.  Fenretinide: induction of apoptosis and endogenous transforming growth factor β in PC-3 prostate cancer cells. Cell Growth Differ. 1997;8:101–111
  8. Chan L-NL, Zhang S, Shao J, Waikel R, Thompson A, Chan T-S. N-(4-Hydroxyphenyl)retinamide induces apoptosis in T lymphoma and T lymphoblastoid leukemia cells. Leuk. Lymphoma. 1997;25:271–280
  9. Di Vinci A, Geido E, Infusini E, Giaretti W. Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl)retinamide. Int. J. Cancer. 1994;59:422–426
  10. Ziv Y, Gupta MK, Milsom JW, Vladisavljevic A, Brand M, Fazio VW. The effect of tamoxifen and fenretinide on human colorectal cancer cell lines in vitro. Anticancer Res. 1994;14:2005–2009
  11. Kalemkerian GP, Slusher R, Ramalingam W, Gadgeel S, Mabry M. Growth inhibition and induction of apoptosis by fenretinide in small cell lung cancer cell lines. J. Natl. Cancer Inst. 1995;87:1674–1680
  12. Kazmi SM, Plante RK, Visconti V, Lau CY. Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid acid receptor-mediated gene expression in human breast cancer cell lines. Cancer Res. 1996;56:1056–1062
  13. Hsieh TC, Ng C, Wu JM. The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) exerts antiproliferative and apoptosis-inducing effects in the androgen-independent human prostatic JCA-1 cells. Biochem. Mol. Biol. Int. 1995;37:499–506
  14. Scher RL, Saito W, Dodge RK, Richtsmeier WJ, Fine RL. Fenretinide-induced apoptosis of human head and neck squamous carcinoma cell lines. Otolaryngeol. Head Neck Surg. 1998;118:464–471
  15. Coradini D, Biffi A, Pellizzaro C, Pirronello E, Di Fronzo G. Combined effect of tamoxifen or interferon-β and 4-hydroxyphenylretinamide on the growth of breast cancer cell lines. Tumour Biol. 1997;18:22–29
  16. Delia D, Aiello A, Lombardi L, Pelicci PG, Grignani F, Formelli GF, et al.  N-(4-hydroxyphenyl)retinamide induces apoptosis of maligant hematopoietic cell lines including those unresponsive to retinoic acid. Cancer Res. 1993;53:6036–6041
  17. Estrov Z, Talpaz M, Zipf TF, Kantarjian HM, Ku S, Ouspenskaia MV, et al.  Role of granulocyte–macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J. Cell Physiol. 1996;166:618–630
  18. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods. 1995;184:39–51
  19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London). 1970;227:680–685
  20. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U.S.A. 1979;76:4350–4354
  21. Gershoni JM, Palade GE. Protein blotting. principles and applications. Anal. Biochem. 1983;131:1–15
  22. Shaw G, Levy PC, LoBuglio AF. Human monocyte antibody-dependent cell-mediated cytotoxicity to tumor cells. Clin. Invest. 1978;62:1172–1180
  23. Estrov Z, Grunberger T, Chan HSL, Freedman MH. Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures. Blood. 1986;67:1382–1387
  24. Estrov Z, Grunberger T, Dube ID, Wang YP, Freedman MG. Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. N. Engl. J. Med. 1986;315:538–542
  25. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KA, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N. Engl. J. Med. 1997;336:317–323
  26. DiPietrantonio AM, Hsieh T-C, Olson SC, Wu JM. Regulation of G1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinide (4-HPR). Int. J. Cancer. 1998;78:53–61
  27. Pollard M, Luckert PH, Sporn MB. Prevention of primary prostate cancer by N-4-hydroxyphenyl retinamide. Cancer Res. 1991;51:3610–3611
  28. Formelli F, Cleris L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res. 1993;53:5374–5376
  29. Sankaranarayanan R, Mathew B. Retinoids as cancer-preventive agents, in: Stewart BW, McGregor D, Keihues P, editors. Principles of chemoprevention. Lyon: IARC; 1996. p. 47.
  30. Lotan R. Retinoids in cancer chemoprevention. FASEB J. 1996;10:1031–1039
  31. Bruno S, Tenca C, Saverino D, Ciccone E, Grossi CE. Apoptosis of squamous cells at different stages of carcinogenesis following 4-HPR treatment. Carcinogenesis. 2002;23:447–456
  32. Follen M, Atkinson EN, Schottenfeld D, Malpica A, West L, Lippman S, et al.  A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin. Cancer Res. 2001;7:3356–3365
  33. Abou-Issa H, Curley RW, Alshafie GA, Weiss KL, Clagett-Dame M, Chapman JS, et al.  Chemotherapeutic evaluation of 4-hydroxybenzylretinone (4-HPR), a nonhydrolyzable C-linked analog of N-(4-hydroxyphenyl)retinamide (4-HPR) against mammary carcinogenesis. Anticancer Res. 2001;21:3839–3844

PII: S0145-2126(02)00162-5

Leukemia Research
Volume 27, Issue 3 , Pages 259-266 , March 2003

Article Tools

* Image Usage & Resolution